Abstract:Patients with septic shock suffer from high mortality rates, particularly when complicated by severe myocardial depression which is characterized by hypotension and a reduction in cardiac output. Inflammation is an important factor involved in the early stages of sepsis. The aim of the present study was to investigate the effect of the Chinese herbal compound puerarin (1, 5, 10, 20 and 40 µM) on cardiomyocyte inflammatory response in a sepsis model using H9c2 cardiomyocytes stimulated with 1 µg/ml lipopolysaccharide (LPS). The mRNA expression levels of tumor necrosis factor (TNF)-α and interleukin (IL)-β were evaluated using reverse transcription-quantitative polymerase chain reaction. In addition, the protein expression levels of various factors were determined using western blot analysis. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling was used to evaluate the apoptosis rates in the various groups, and immunocytochemical analysis was employed to determine the effect of puerarin on the nuclear translocation of p65 protein. The present study demonstrated that LPS stimulation increased IL-1β and TNF-α mRNA expression levels, as compared with the controls (P<0.05). Following treatment with various concentrations of puerarin, the expression levels of IL-1β and TNF-α were markedly blunted, particularly in the LPS + 40 µM puerarin group (P<0.05 vs. the LPS group). Furthermore, puerarin administration significantly inhibited LPS-induced apoptosis in H9c2 cardiomyocytes, as determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining (TUNEL positive cells: LPS + 40 µM puerarin group, 5.5% vs. LPS group, 10.5%; P<0.01). In addition, puerarin significantly decreased LPS-induced phosphorylated nuclear factor (p-NF)-κB p65 and Bax expression levels, and increased the expression levels of Bcl-2, as compared with the LPS group (P<0.05). These data indicated that puerarin may serve as a valuable protective agent against cardiovascular inflammatory diseases.

Clinical analysis of 5 cases with acute intravascular hemolysis caused by puerarin

Role of the interaction between puerarin and the erythrocyte membrane in puerarin-induced hemolysis

Puerarin-induced immune hemolytic anemia

Puerarin protects human umbilical vein endothelial cells against high glucose-induced apoptosis by upregulating heme oxygenase-1 and inhibiting calpain activation.

[Experimental Factors Affecting in Vitro Recovery of Puerarin in Microdialysis].

The Study to Reduce the Hemolysis Side Effect of Puerarin by a Submicron Emulsion Delivery System

Protective Effect of Puerarin Form the Roots of Pueraria Lobata Against Systemic Inflammatory Response Syndrome by Regulating the Levels of Related Cytokines

Exploring adverse effects of puerarin on catalase by multiple spectroscopic investigations and docking studies in vitro

Effect of Puerarin on Calcium Overload in Cultured Human Umbilical Vascular Endothelial Cells

Effects of Puerarin with Aspirin on the Markers of Damaged Vascular Endothelial Cells in Patients with Acute Cerebral Infarction

[Effect of Puerarin on platelet activating factors CD63 and CD62P, plasminogen activator inhibitor and C-reactive protein in patients with unstable angia pectoris]

Pharmacological Activity, Pharmacokinetics, and Clinical Research Progress of Puerarin

Puerarin Attenuates the Inflammatory Response and Apoptosis in LPS-stimulated Cardiomyocytes.

Effects of puerarin on monoamino neurotransmitter levels in the striatum of cerebral ischemia rats

Inhibition of Puerarin on the H2O2-induced Apoptosis of Smooth Muscle Cells

Puerarin Protects Against Ischemic Brain Injury in a Rat Model of Transient Focal Ischemia

Puerarin: a hepatoprotective drug from bench to bedside

[Research on Hemorheology in Rats with Acute Hyperuricemia].

Protective Effect of Puerarin Against Myocardial Reperfusion Injury. Myocardial Metabolism and Ultrastructure.

Protective Effect of Puerarin on Lung Ischemia-Reperfusion Injury

Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases